Last reviewed · How we verify

NCT05432661: HFNO

clınıcal Effects of High-flow Nasal Oxygen Use ın gerıatrıc patıents

Status unknown Last updated 27 June 2022
What this trial tests

trial testing HİGH-FLOW NASAL OXYGEN USE (HFNO) in Biliary Obstruction in 120 participants. Status unknown.

Timeline
14 June 2022
Primary endpoint
15 July 2022
25 July 2022

Quick facts

Lead sponsorYunus Emre
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment120
Start date14 June 2022
Primary completion15 July 2022
Estimated completion25 July 2022

Drugs / interventions tested

Conditions studied

Sponsor

Yunus Emre — full company profile →

Who can join

Adults 65 to 90, any sex, with Biliary Obstruction or Oddi's Sphincter Constriction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is designed to monitor the efficacy of nasal cannula or hıgh-flow nasal oxygen in geriatric patients for endoscopıc retrograde cholangıopancreatography procedures. The aim of the study is to evaluate the efficacy and safety of oxygen support obtained with low-flow nasal cannula and hıgh-flow nasal oxygen during endoscopıc retrograde cholangıopancreatography in the patient group at risk for adverse respiratory events. We hypothesized that high-flow nasal oxygen administration can prevent adverse respiratory events such as deep sedation and patient position that may endanger the airway safety of patients, and reduce the problems in cardiac and hemodynamic parameters that may develop.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Biliary Obstruction

Currently open trials in the same condition.

Other Yunus Emre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05432661.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing